130 related articles for article (PubMed ID: 15835749)
1. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.
Haynes A; Shaik MS; Chatterjee A; Singh M
Pharm Res; 2005 Mar; 22(3):427-39. PubMed ID: 15835749
[TBL] [Abstract][Full Text] [Related]
2. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Fulzele SV; Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2006 Mar; 58(3):327-36. PubMed ID: 16536899
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line.
Haynes A; Shaik MS; Chatterjee A; Singh M
Pharm Res; 2003 Sep; 20(9):1485-95. PubMed ID: 14567645
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.
Patel AR; Chougule MB; I T; Patlolla R; Wang G; Singh M
Pharm Res; 2013 May; 30(5):1435-46. PubMed ID: 23361589
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Shaik MS; Chatterjee A; Jackson T; Singh M
Int J Cancer; 2006 Jan; 118(2):396-404. PubMed ID: 16052515
[TBL] [Abstract][Full Text] [Related]
6. Inhalation delivery of anticancer agents via HFA-based metered dose inhaler using methotrexate as a model drug.
Shaik MS; Haynes A; McSween J; Ikediobi O; Kanikkannan N; Singh M
J Aerosol Med; 2002; 15(3):261-70. PubMed ID: 12396414
[TBL] [Abstract][Full Text] [Related]
7. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Ichite N; Singh M
Anticancer Drugs; 2007 Jan; 18(1):65-78. PubMed ID: 17159504
[TBL] [Abstract][Full Text] [Related]
8. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Singh M
Pharm Res; 2006 Sep; 23(9):2094-106. PubMed ID: 16902813
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Choe MS; Chen Z; Klass CM; Zhang X; Shin DM
Clin Cancer Res; 2007 May; 13(10):3015-23. PubMed ID: 17505004
[TBL] [Abstract][Full Text] [Related]
10. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
[TBL] [Abstract][Full Text] [Related]
11. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
Park JS; Jun HJ; Cho MJ; Cho KH; Lee JS; Zo JI; Pyo H
Clin Cancer Res; 2006 Aug; 12(16):4989-99. PubMed ID: 16914589
[TBL] [Abstract][Full Text] [Related]
13. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Chen L; He Y; Huang H; Liao H; Wei W
Med Oncol; 2008; 25(2):161-71. PubMed ID: 18172786
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Sievers EM; Bart RD; Backhus LM; Lin Y; Starnes M; Castanos R; Starnes VA; Bremner RM
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1242-9. PubMed ID: 15942563
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
[TBL] [Abstract][Full Text] [Related]
17. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
[TBL] [Abstract][Full Text] [Related]
18. [Effects of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer].
Xia H; Ye J; Bai H; Wang C
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):625-31. PubMed ID: 24345486
[TBL] [Abstract][Full Text] [Related]
19. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Bijman MN; Hermelink CA; van Berkel MP; Laan AC; Janmaat ML; Peters GJ; Boven E
Biochem Pharmacol; 2008 Jan; 75(2):427-37. PubMed ID: 17936723
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
